Independence Blues creates provider network for costly gene therapies

Independence Blue Cross is launching a network to manage the cost and outcomes of gene-based therapies with Philadelphia-based Penn Medicine and Children's Hospital of Philadelphia, reports Becker’s Payer Issues. Gene-based therapies can treat rare genetic conditions but come with sky-high price tags. Independence Blue Cross is also pursuing outcome-based agreements with drug manufacturers for new gene-based drugs coming to market, the insurer said.